Glutathione Peroxidase-1 and Homocysteine for Cardiovascular Risk Prediction
Results from the AtheroGene Study
Renate Schnabel, MD*,*,
Karl J. Lackner, MD
,
Hans J. Rupprecht, MD*,
Christine Espinola-Klein, MD*,
Michael Torzewski, MD
,
Edith Lubos, MD*,
Christoph Bickel, MD
,
François Cambien, MD
,
Laurence Tiret, PhD
,
Thomas Münzel, MD, FAHA* and
Stefan Blankenberg, MD*
* Department of Medicine II, Johannes Gutenberg-University, Mainz, Germany
Department of Clinical Chemistry and Laboratory Medicine, Johannes Gutenberg-University, Mainz, Germany
INSERM U525, Faculté de Médecine Pitié-Salpétrière, Paris, France
Innere Abteilung, Bundeswehrzentralkrankenhaus, Koblenz, Germany

View larger version (28K):
[in a new window]
|
Figure 1 Kaplan-Meier curves showing cardiovascular events in the subgroups of patients classified according to median baseline levels of homocysteine (HCY) and baseline activity of glutathione peroxidase (GPx)-1.
|
|

View larger version (14K):
[in a new window]
|
Figure 2 Hazard ratios (95% confidence interval) associated with classic risk factors in a multivariate model and with homocysteine and glutathione peroxidase (GPx)-1 (increase per one standard deviation) on top of classic risk factors (each marker added separately to classic risk factors). In addition, the area under the curve (AUC) of the corresponding multivariate model is provided. HDL = high-density lipoprotein.
|
|
Copyright © 2005 by the American College of Cardiology Foundation.